Chinese Biopharma Surges as Capital Pivots Away From AI

BeOne Medicines led the charge in Shanghai with a 10% gain, while Hong Kong-listed Hengrui Pharmaceuticals followed closely with a 9.8% climb. The momentum swept across the industry, lifting major players like WuXi AppTec, Innovent Biologics, and CSPC Pharmaceutical between 5% and 7%. Smaller firms saw even more aggressive movement, as Junshi Biosciences and Biocytogen Pharmaceuticals jumped 15% and 20% respectively.

Market sentiment was further bolstered by the debut of Alebund Pharmaceuticals in Hong Kong, which saw its IPO 900 times oversubscribed. Morningstar analyst Kai Wang noted that this immense demand signaled continued government commitment to the domestic drug sector. Simultaneously, Nomura analyst Jialin Zhang pointed to the publication of a preliminary list for the national medical insurance drug catalog as a key catalyst, as it expands the commercial coverage potential for innovative new therapies.

Despite the enthusiasm, some analysts remain cautious about the sustainability of the movement. Jefferies head of Asia healthcare, Cui Cui, characterized the sudden inflow as a tactical reallocation of funds rather than a fundamental shift in business performance. While the Hang Seng Biotech Index finished the session up 6.7%, investors are now weighing whether this policy-backed support will provide enough stability to sustain valuations as the AI-driven capital flight settles.